MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2022 International Congress

    Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…
  • 2022 International Congress

    Exploring the morning akinesia in Parkinson’s disease with the wearable sensor STAT-ON

    N. Caballol, C. Pérez-López, A. Pérez-Soriano, A. Planas-Ballvé, A. ávila, P. Quispe, A. Bayés (Sant Joan Despí, Spain)

    Objective: To detect the morning akinesia (MA) through the analysis of the gait fluidity (GF) measured by the sensor STAT-ON. Background: The STAT-ON sensor's detection…
  • 2022 International Congress

    Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…
  • 2022 International Congress

    Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status

    R. Barbosa, M. Medonça, R. Oliveira, M. Santos, A. Abreu, P. Bastos, P. Pita-Lobo, A. Valadas, L. Correia-Guedes, J. Ferreira, M. Rosa, R. Matias, M. Coelho (Lisbon, Portugal)

    Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…
  • MDS Virtual Congress 2021

    Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease

    C. Tanner, J. Lytle, A. Formella (San Francisco, USA)

    Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…
  • MDS Virtual Congress 2021

    Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results

    T. Fay-Karmon, N. Galor, B. Heimler, R. Bartsch, A. Zilka, V. Livneh, M. Plotnik, S. Hassin-Baer (Ramat Gan, Israel)

    Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…
  • MDS Virtual Congress 2021

    Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…
  • MDS Virtual Congress 2021

    Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications

    D. Kremens, W. Oertel, R. Pahwa, R. Hauser, C. Lecureuil, R. Johnson, G. Went (Philadelphia, USA)

    Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…
  • MDS Virtual Congress 2021

    Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

    CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)

    Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
  • MDS Virtual Congress 2021

    Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease

    W. Oertel, R. Pahwa, R. Hauser, M. Sale, G. Went (Marburg, Germany)

    Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Unusual prolonged survival in multiple system atrophy: A case report
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley